These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 24332210)

  • 1. Investigating the potential impact of four-dimensional computed tomography (4DCT) on toxicity, outcomes and dose escalation for radical lung cancer radiotherapy.
    Cole AJ; O'Hare JM; McMahon SJ; McGarry CK; Butterworth KT; McAleese J; Jain S; Hounsell AR; Prise KM; Hanna GG; O'Sullivan JM
    Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):142-50. PubMed ID: 24332210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
    Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
    Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
    Liao ZX; Komaki RR; Thames HD; Liu HH; Tucker SL; Mohan R; Martel MK; Wei X; Yang K; Kim ES; Blumenschein G; Hong WK; Cox JD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):775-81. PubMed ID: 19515503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of four-dimensional (4D) Monte Carlo dose calculation in real-time tumor tracking stereotatic body radiotherapy for lung cancers.
    Chan MK; Kwong DL; Ng SC; Tam EK; Tong AS
    Med Phys; 2012 Sep; 39(9):5479-87. PubMed ID: 22957615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
    Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.
    Marnitz S; Stuschke M; Bohsung J; Moys A; Reng I; Wurm R; Budach V
    Strahlenther Onkol; 2002 Nov; 178(11):651-8. PubMed ID: 12426677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer.
    Lavrenkov K; Christian JA; Partridge M; Niotsikou E; Cook G; Parker M; Bedford JL; Brada M
    Radiother Oncol; 2007 May; 83(2):156-62. PubMed ID: 17493699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the planning target volume based on three-dimensional CT and four-dimensional CT images of non-small-cell lung cancer.
    Li FX; Li JB; Zhang YJ; Liu TH; Tian SY; Xu M; Shang DP; Ma CS
    Radiother Oncol; 2011 May; 99(2):176-80. PubMed ID: 21549440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of target volume segmentation accuracy and variability on treatment planning for 4D-CT-based non-small cell lung cancer radiotherapy.
    Martin S; Johnson C; Brophy M; Palma DA; Barron JL; Beauchemin SS; Louie AV; Yu E; Yaremko B; Ahmad B; Rodrigues GB; Gaede S
    Acta Oncol; 2015 Mar; 54(3):322-32. PubMed ID: 25350526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets.
    Underberg RW; Lagerwaard FJ; Slotman BJ; Cuijpers JP; Senan S
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):554-60. PubMed ID: 15890600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
    Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
    Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhomogeneous dose escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose.
    Nielsen TB; Hansen O; Schytte T; Brink C
    Acta Oncol; 2014 Jan; 53(1):119-25. PubMed ID: 23627917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating heterogeneity correction and 4DCT in lung stereotactic body radiation therapy (SBRT): The effect on target coverage, organ-at-risk doses, and dose conformity.
    Franks KN; Purdie TG; Dawson LA; Bezjak A; Jaffray DA; Bissonnette JP
    Med Dosim; 2010; 35(2):101-7. PubMed ID: 19931021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer.
    Murshed H; Liu HH; Liao Z; Barker JL; Wang X; Tucker SL; Chandra A; Guerrero T; Stevens C; Chang JY; Jeter M; Cox JD; Komaki R; Mohan R
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1258-67. PubMed ID: 15001271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isotoxic dose escalation in the treatment of lung cancer by means of heterogeneous dose distributions in the presence of respiratory motion.
    Baker M; Nielsen M; Hansen O; Jahn JW; Korreman S; Brink C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):849-55. PubMed ID: 21570211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.